TrialCurveASTRUM-002 (final overall survival): reconstructed Kaplan–Meier curves
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancer Commun (Lond). 2026 Jun 10;46:0034. doi: 10.34133/cancomm.0034 |
|---|---|
| DOI | 10.34133/cancomm.0034 |
| Registry | NCT03952403 |
| Phase | Phase 3 |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Interventions | HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed |
| Sponsor | Shanghai Henlius Biotech |
| Enrolment | 643 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival (BICR-assessed) — ITT population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Group B 10.6 months; Group A 11.2 months; Group C 5.7 months. Survival at 18 months: Group B 37%; Group A 37%; Group C 17%. Hazard ratio Group B vs Group C 0.53 (95% CI 0.42–0.67).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Group B | 214 | 144 | 10.6 |
| Group A | 212 | 153 | 11.2 |
| Group C | 210 | 168 | 5.7 |
- Group B vs Group C: reconstructed HR 0.53 (95% CI 0.42–0.67)
- Group A vs Group C: reconstructed HR 0.53 (95% CI 0.42–0.66)
Landmark survival (reconstructed)
| Time | Group B | Group A | Group C |
|---|---|---|---|
| 6 mo | 68.8% | 73.1% | 48.1% |
| 12 mo | 43.7% | 49.4% | 25.2% |
| 18 mo | 37.2% | 37.1% | 17.0% |
| 24 mo | 29.7% | 25.4% | 10.9% |
| 36 mo | 22.7% | 18.3% | 6.6% |
| 48 mo | 19.2% | 14.7% | 3.2% |
Checks against the published figure
- Group A median: printed 12, reconstructed 11.2 pass
- Group B median: printed 11, reconstructed 10.6 pass
- Group C median: printed 5.7, reconstructed 5.65 pass
- hazard ratio: printed 1.02, reconstructed 1.03 pass
- hazard ratio: printed 0.54, reconstructed 0.532 pass
Overall survival — ITT population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Group B 26.1 months; Group A 23.7 months; Group C 20.2 months. Survival at 18 months: Group B 63%; Group A 62%; Group C 53%. Hazard ratio Group B vs Group C 0.67 (95% CI 0.53–0.84).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Group B | 214 | 133 | 26.1 |
| Group A | 212 | 142 | 23.7 |
| Group C | 210 | 163 | 20.2 |
- Group B vs Group C: reconstructed HR 0.67 (95% CI 0.53–0.84)
- Group A vs Group C: reconstructed HR 0.75 (95% CI 0.59–0.93)
Landmark survival (reconstructed)
| Time | Group B | Group A | Group C |
|---|---|---|---|
| 6 mo | 91.0% | 87.7% | 83.1% |
| 12 mo | 74.6% | 75.2% | 65.4% |
| 18 mo | 63.0% | 62.1% | 53.4% |
| 24 mo | 52.3% | 48.3% | 44.6% |
| 36 mo | 39.9% | 36.6% | 31.0% |
| 48 mo | 33.6% | 29.9% | 16.0% |
| 60 mo | 32.5% | — | 13.9% |
Checks against the published figure
- Group A median: printed 23.7, reconstructed 23.7 pass
- Group B median: printed 26.8, reconstructed 26.1 pass
- Group C median: printed 20.3, reconstructed 20.2 pass
- hazard ratio: printed 1.12, reconstructed 1.11 pass
- hazard ratio: printed 0.66, reconstructed 0.669 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/astrum-002-final-overall-survival-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/astrum-002-final-overall-survival-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Cancer Commun (Lond). 2026 Jun 10;46:0034. doi: 10.34133/cancomm.0034 doi:10.34133/cancomm.0034. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/astrum-002-final-overall-survival
Report a problem with these data
Related trials
- ETER701: Overall survival; Progression-free survival (PFS)
- TOPICAL: Overall survival; Progression-free survival
- LUNGSTAR: Overall survival; Progression-free survival
- Socazolimab + chemotherapy in extensive-stage SCLC: Overall survival; Progression-free survival (IRRC, RECIST v1.1)
- Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
- CA209-7AL: Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials